Acusphere Inc
OTC:ACUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acusphere Inc
Change in Working Capital
Acusphere Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acusphere Inc
OTC:ACUS
|
Change in Working Capital
$15.4m
|
CAGR 3-Years
35%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Change in Working Capital
-$12.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Change in Working Capital
-$455m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
5%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Change in Working Capital
-$5.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Change in Working Capital
-$7B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-39%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Change in Working Capital
-$8.1B
|
CAGR 3-Years
-2 063%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-22%
|
|
Acusphere Inc
Glance View
Acusphere, Inc. is a pharmaceutical company, which engages in the development of drugs and formulations of existing drugs using proprietary micro particle technology. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2003-10-08. The firm is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The firm's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The firm has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
See Also
What is Acusphere Inc's Change in Working Capital?
Change in Working Capital
15.4m
USD
Based on the financial report for Dec 31, 2008, Acusphere Inc's Change in Working Capital amounts to 15.4m USD.
What is Acusphere Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
48%
The average annual Change in Working Capital growth rates for Acusphere Inc have been 35% over the past three years , 48% over the past five years .
